Carisoprodol - Comprehensive Usage Guide: instructions, indications, composition, side effects

• Active Ingredient: Carisoprodol
• Excipients: May include microcrystalline cellulose, magnesium stearate, starch, and other inactive ingredients depending on the formulation.

• Tablets: Available in various strengths, including 250 mg and 350 mg tablets.

Carisoprodol belongs to the pharmacological group of muscle relaxants (ATC code: M03B A02).

• Pharmacodynamics: Carisoprodol acts centrally as a muscle relaxant by exerting its effects on the central nervous system, particularly the spinal cord, resulting in sedation and alteration of pain perception.
• Pharmacokinetics: Following oral administration, carisoprodol is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 1 to 2 hours. It is metabolized in the liver to its active metabolite, meprobamate, which contributes to its pharmacological effects. Carisoprodol and its metabolites are primarily excreted in the urine.

Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Carisoprodol is contraindicated in individuals with:

• Hypersensitivity to carisoprodol or any component of the formulation.
• Porphyria.
• Acute intermittent porphyria.
• Severe hepatic impairment.

Carisoprodol may interact with other medications, including:

• Central nervous system depressants, such as alcohol, benzodiazepines, and opioids, leading to additive sedative effects.
• Drugs that inhibit CYP2C19 enzymes, such as omeprazole and fluvoxamine, potentially increasing carisoprodol concentrations and the risk of adverse effects.

• Carisoprodol tablets should be taken orally with or without food, usually three times daily and at bedtime, as directed by a healthcare provider.
• The dosage and duration of therapy depend on the severity of the musculoskeletal condition and individual patient response.
• Treatment duration should be limited to 2 to 3 weeks due to the risk of dependence, tolerance, and withdrawal symptoms.

• Carisoprodol should be avoided during pregnancy, especially during the first trimester, unless the potential benefits outweigh the risks.
• It may be excreted in breast milk, so breastfeeding is not recommended during treatment with carisoprodol.

• Dosage adjustments may be necessary in patients with hepatic impairment to avoid drug accumulation and potential toxicity.
• Abrupt discontinuation of carisoprodol after prolonged use may result in withdrawal symptoms, so gradual tapering of the dose is recommended.

In case of overdose, supportive measures should be initiated, and medical attention should be sought immediately. Symptoms of overdose may include drowsiness, dizziness, confusion, respiratory depression, and coma.

Common side effects of carisoprodol may include:

• Drowsiness
• Dizziness
• Headache
• Dry mouth
• Nausea

Carisoprodol tablets should be stored at controlled room temperature (20-25°C) in a dry place, protected from light and moisture. The expiration date should be checked before use.

These comprehensive instructions provide essential information on the composition, pharmacological properties, indications, contraindications, interactions, administration, side effects, and storage of carisoprodol, aiding healthcare professionals and patients in safe and effective medication use. Always consult a healthcare provider for personalized medical advice.